Clinical Trial

A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran

Name: A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran — clinical trial record (NCT07553442)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.

Protocol Amendment History 1 change

critical Recruitment opened 2026-05-15

Trial Details

NCT Number	NCT07553442
Lead Sponsor	Alnylam Pharmaceuticals Collaborators: Hoffmann-La Roche
Conditions	Hypertension
Enrollment	93 participants
Start Date	2026-04-27
Primary Completion	2028-04-01 (estimated)
Study Completion	2028-10-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-14